<?xml version="1.0" encoding="UTF-8"?>
<notes id="n1">
 <p>Specific author contribution: FS, GI, and AA designed the project. FS, GI, GP, LRL, LMV, VP, YR, and IB performed the literature reseach and wrote the manuscript. DP, MN, GC, YR, GC, AG, and AA also contributed to literature research and to revise critically the manuscript. All authors reviewed and approved the final draft of the article before submission. AA oversaw the project and guarantees for the integrity of the work.</p>
 <p>Conflicts of interest: FS: advisory board for Abbvie, Janssen, MSD, Sanofi, Takeda. GP received consultancy fees from Alphasigma. VP is in scientific advisory board of Actial Farmaceutica Srl, Italy. DP received speaker fees from AbbVie, MSD, Takeda and Janssen, Pfizer. GC: consultant for and food and beverage compensation from Cook Medical, Boston Scientific, and Olympus. AG reports personal fees for consultancy for Eisai S.r.l., 3PSolutions, Real Time Meeting, Fondazione Istituto Danone, Sinergie S.r.l. Board MRGE, and Sanofi S.p.A, personal fees for acting as a speaker for Takeda S.p.A, AbbVie, and Sandoz S.p.A, and personal fees for acting on advisory boards for VSL3 and Eisai. IB: consultant for Apollo Endosurgery, Cook Medical, and Boston Scientific; board member for Endo Tools; research grant recipient from Apollo Endosurgery; food and beverage compensation from Apollo Endosurgery, Cook Medical, Boston Scientific, and Endo Tools. AA: consulting and/or advisory board fees from AbbVie, Allergan, Amgen, Biogen, Bristol-Myers Squibb, Celgene, Celltrion, Ferring, Gilead, Janssen, Lilly, MSD, Mylan, Pfizer, Samsung Bioepis, Sandoz, Takeda; lecture and/or speaker bureau fees from AbbVie, Amgen, Biogen, Ferring, Giliead, Janssen, MSD, Mitsubishi-Tanabe, Nikkiso, Pfizer, Sandoz, Samsung Bioepis, Takeda; and research grants from MSD, Pfizer, Takeda. All the other authors have no potential conflicts of interest to disclose.</p>
</notes>
